Peptide-powered wellness.
Direct-pay telehealth, 48 states + DC.
Program · PCOS
Physician-supervised evaluation for the insulin-resistance and weight-retention components of PCOS. Dose-titrated to the individual by a licensed physician. Telehealth in 48 US states + DC (AK and MS not served).
PCOS affects roughly one in ten women of reproductive age. The cycle irregularity, androgen excess, hirsutism, and weight that come with it all trace back to the same metabolic axis: hyperinsulinemia drives the ovary to overproduce androgens. Improving insulin sensitivity and reducing body weight are the two interventions with the most consistent evidence in PCOS — and GLP-1 receptor agonists do both.
~28% lower free testosterone
Pooled GLP-1 PCOS trials (Cena et al., 2024 meta-analysis) reported ~28% reductions in free testosterone — the downstream signal of improved insulin sensitivity.
18.8% median weight loss
A 4,241-woman UK real-world tirzepatide cohort (2025) reported 18.8% median weight loss at ten months in women with PCOS — with 91% reaching ≥10% loss.
~68% better menstrual regularity
Pooled PCOS trial data show ~68% improvement in menstrual regularity and ~55% increase in ovulation rates — largest among patients losing ≥10% body weight.
Mechanism
The Rotterdam criteria define PCOS clinically by some combination of irregular cycles, biochemical or clinical hyperandrogenism, and polycystic ovarian morphology. But underneath the diagnostic criteria, the dominant mechanism in the majority of cases is insulin resistance. Insulin and related growth-factor signaling affect ovarian theca cells; chronically elevated insulin pushes androgen synthesis up and suppresses sex-hormone binding globulin, which raises free testosterone and amplifies the phenotype.
GLP-1 receptor agonists work on two arms at once: they improve insulin sensitivity (lowering the upstream driver) and produce clinically meaningful weight loss (which independently improves insulin signaling). Among medications used in PCOS, this dual mechanism is unusually well-matched to the underlying pathophysiology.
Clinical evidence
The clearest evidence base in PCOS is for liraglutide — multiple RCTs since 2014 have shown weight loss, improved insulin resistance, and improved menstrual regularity. Semaglutide and tirzepatide are newer in this indication but the evidence has compounded fast since 2022: small RCTs and real-world cohorts consistently report 10–15% weight loss at six months, large drops in HOMA-IR, reductions in free androgen index, and meaningful improvements in cycle regularity.
The 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome — the global standard-of-care document co-published by ESHRE, the Endocrine Society, the ASRM, and the Monash Centre for Health Research — formally recognizes GLP-1 receptor agonists as an option for weight management in women with PCOS who have not responded to lifestyle intervention. That guideline shifted GLP-1 from off-protocol to inside the international standard for PCOS care.
Who it's for
Fertility timing — read this carefully
GLP-1 receptor agonists are not used during conception, pregnancy, or breastfeeding. If you are planning to conceive, current labeling guidance is to discontinue semaglutide at least two months before a planned pregnancy; tirzepatide guidance is similar. If TTC is on your near-term horizon, tell your physician during intake — the protocol gets planned around your fertility window, not the other way around. Many women with PCOS use GLP-1 to lose weight and improve cycle regularity first, then wash out before TTC. That sequence is common and appropriate.
Related programs & reading
Drug · GLP-1
The most-studied GLP-1 in PCOS so far. Weekly subcutaneous, dose-titrated.
Drug · GLP-1/GIP
Dual-receptor protocol — often deeper weight loss when significant reduction is the goal.
Sibling hub
Lower-dose protocols — useful when weight loss is secondary to insulin and cycle goals.
Read · Pillar
The pillar article — trial summaries, effect sizes, and the 2023 guideline change.
FAQ
PCOS is, at its metabolic core, an insulin-resistance condition. Hyperinsulinemia drives ovarian theca cells to overproduce androgens, which in turn drive the cycle irregularity, hirsutism, acne, and weight retention many women with PCOS experience. GLP-1 receptor agonists improve insulin sensitivity, lower fasting insulin, and produce clinically meaningful weight loss — all of which directly address the mechanism that drives PCOS symptoms. Because 5–10% body weight loss alone can restore ovulation in a large fraction of women with PCOS, the weight-loss arm of GLP-1 therapy is often as clinically valuable as the insulin arm.
Randomized and observational trials of semaglutide and tirzepatide in women with PCOS have reported significant improvements in body weight, HOMA-IR (a marker of insulin resistance), free androgen index, and menstrual regularity. The 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome — the global standard-of-care document — formally recognizes GLP-1 RAs as a treatment option for weight management in women with PCOS who have not responded sufficiently to lifestyle intervention. Individual response varies, and effect sizes depend on baseline weight, duration of therapy, and adherence.
No medication can guarantee that. What the evidence does show is that the combination of weight loss and improved insulin sensitivity produced by GLP-1 therapy is associated with more regular cycles and higher ovulation rates in many women with PCOS. The physician will not promise a specific cycle outcome — the goal is to address the underlying metabolic dysfunction and let the downstream effects follow. If cycle restoration is a primary goal, your physician may also discuss other options (lifestyle, inositol, metformin) and how they layer with GLP-1.
No. GLP-1 receptor agonists are not appropriate during conception, pregnancy, or breastfeeding. Patients planning to conceive must wash out the medication before trying — current labeling guidance is to discontinue semaglutide at least two months before a planned pregnancy, and the washout for tirzepatide is comparable. This is one of the most important conversations to have during intake — if your timeline includes TTC, the physician will plan the protocol around your fertility window, not the other way around.
Operationally it uses the same medications (compounded semaglutide or tirzepatide), but the clinical reasoning is different. The physician pays closer attention to insulin-resistance markers (HOMA-IR, fasting insulin, A1c), androgen markers (free testosterone, DHEA-S, SHBG), and cycle history. Dose decisions weigh these alongside scale weight. Many women with PCOS do well at lower doses than the trial-curve target dose — microdose protocols are explicitly an option here when significant weight loss is not needed.
Metformin and myo-inositol both improve insulin sensitivity through different mechanisms and are widely used in PCOS care. They are not exclusive with GLP-1 — many patients stack them. Your physician will review what you are already taking and what makes sense to add, continue, or change. The decision is made individually; the physician will not push or remove an existing medication without medical reason.
The side-effect profile is the same as for the general weight-loss population: nausea, reduced appetite, occasional gastrointestinal disruption, and rare but serious risks (pancreatitis, gallbladder issues, certain thyroid contraindications). PCOS patients with a history of gastroparesis, prior bariatric surgery, or significant gallbladder disease should disclose that during intake — these are common comorbidities and they change the dose plan.
The PCOS program uses the same pricing as the Microdose GLP-1 track — $149/month on a monthly basis, $137/month with a 6-month commitment, or $134/month with an annual commitment. There is no separate "PCOS surcharge." The physician determines the appropriate medication and dose during intake.
The protocol is delivered via telehealth in 48 US states and the District of Columbia (Alaska and Mississippi are not currently served). Initial intake, physician review, prescription, and follow-up visits are all conducted online. Lab work — when the physician orders it — is sent to a local Quest or Labcorp draw site. In-person care is not required to enroll, but the physician may recommend an in-person GYN or endocrinology visit alongside the program if the clinical picture warrants it.
Compounded preparations are NOT FDA-approved drugs, are NOT generic versions of branded medications, and are not represented as therapeutically equivalent to any FDA-approved product. They are prepared by licensed 503A or 503B compounding pharmacies under specific federal rules. Whether a compounded preparation is clinically appropriate for a given patient is an individualized clinical decision made by the prescribing physician. TelePeptide does not sell, distribute, or supply branded medications.
Start here
Six questions identifies your PCOS phenotype and shows whether semaglutide, tirzepatide, or a microdose protocol fits your profile. Free, takes about a minute.
Or just get the guide by email
Informational only — not medical advice. GLP-1 use for PCOS is off-label and supported by the 2023 International Evidence-Based PCOS Guideline as an option for weight management. We don't share your email; unsubscribe in one click.
Next Step
A licensed physician will review your goals and recommend the right protocol — peptide wellness, recomposition, or supervised weight loss. No insurance, no waiting room.
Compounded medications are prepared by licensed 503A pharmacies. Prescribing decisions are made solely by licensed clinicians based on individual medical necessity. These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved. GLP-1 use for PCOS is supported by the 2023 International Evidence-Based Guideline for PCOS as an option for weight management in women who have not responded to lifestyle intervention. GLP-1 medications are not used during pregnancy or breastfeeding. Patients planning to conceive must wash out the medication per current labeling before TTC.